fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

INM

InMed Pharmaceuticals, Inc.

  ( )

Page Views : 133381

company profile

 

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.  

Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.

Unlike natural cannabinoids isolated from the plant which are not patentable, InMed’s proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. They are screening these analogs for their therapeutic properties and pharmaceutical development.

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. They have engineered bioidentical cannabinoids with high purity and consistency, and free of THC.They currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBT) which are available for B2B purchase. They recently reported $1M in quarterly revenues in Q3, which was  the first time they exposed this level from the sales of rare cannabinoids to the Health and Wellness (“H&W”) sector, representing a 120% increase over 2Q sales.

www.inmedpharma.com.

Analyst Ratings

 
Buy
Strong Buy
0 %
Buy
100 %
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
Sector
:
Healthcare
Industry
:
Biotechnology
Exchange
:
Nasdaq
Ticker
:
INM

vista's key points

  • InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
  • InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
  • Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
  • InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
  • InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa (EB), and two preclinical programs in glaucoma and neurodegenerative disease.
  • InMed Completed enrollment in Phase 2 Clinical Trial for epidermolysis bullosa; data readout expected during calendar 3Q 2023.
  • InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
  • InMed sponsored research, entitled "Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare cannabinoid ("pCBx") in InMed's 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer's.
  • Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids.
  • InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
  • InMed's BayMedica continues to be a leading producer of cannabichromene (CBC) with increased revenue in the last 3Q's,120% quarter-over-quarter revenue growth in Q3 & continues to evaluate strategic options/long-term supply agreements for this business segment.
  • At March 31, 2023, InMed's total issued and outstanding shares were 3,328,191.
  • On March 13, InMed announced that a peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International Journal of Molecular Sciences.
  • At March 31, 2023, Inmed's cash, cash equivalents and short-term investments were $9.6 million, which compares to $6.2 million at June 30, 2022.